Fisetin is a flavonoid found in strawberries, apples, and persimmons that has attracted research attention as a potential senolytic agent — a compound that may selectively clear senescent, or ‘zombie,’ cells from the body. Early preclinical studies and a small number of human trials have explored its possible role in reducing age-related frailty and inflammation. As interest in high-dose fisetin supplementation grows, so does a critical but underappreciated question: how does fisetin interact with prescription medications?
The answer centers largely on the cytochrome P450 (CYP) enzyme system — the liver’s primary machinery for metabolizing most drugs. If fisetin inhibits key CYP enzymes, it can alter how the body processes medications ranging from anticoagulants like warfarin to statins, immunosuppressants, and certain antidepressants. This article examines what the available evidence says about fisetin’s interactions with CYP enzymes and blood-thinning drugs, and identifies who should exercise particular caution. This is informational content, not medical advice.
Key Takeaways
- Fisetin, as a constituent of Rhus verniciflua and as a standalone flavonoid, has been shown in laboratory studies to inhibit human cytochrome P450 enzymes [2], which are central to how most prescription drugs are metabolized.
- CYP2C9 and CYP3A4 inhibition is the primary theoretical pathway by which fisetin could elevate plasma concentrations of drugs like warfarin, certain statins, immunosuppressants, and other CYP-sensitive medications.
- High-dose intermittent senolytic protocols amplify interaction risk compared with low dietary doses, because peak plasma fisetin concentrations are substantially higher — but human pharmacokinetic data remain sparse.
- Anyone taking anticoagulants, antiplatelets, immunosuppressants, or any drug with a narrow therapeutic window should consult a physician or pharmacist before adding fisetin supplementation.
- Fisetin is not FDA-approved to treat or prevent any disease; available evidence for human benefit is preliminary, and the safety of senolytic dosing protocols in people on polypharmacy has not been established in controlled trials.
How the CYP Enzyme System Controls Drug Metabolism
The cytochrome P450 superfamily comprises dozens of liver enzymes responsible for metabolizing roughly 70 to 80 percent of all clinically used drugs. These enzymes — especially CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 — chemically transform drugs into water-soluble metabolites that can be excreted. When something interferes with these enzymes, two scenarios emerge: if the enzyme is inhibited, the drug accumulates to higher concentrations than intended, potentially causing toxicity; if the enzyme is induced, the drug clears faster and therapeutic levels may not be reached.
Botanical compounds, including many flavonoids, are among the most common natural CYP inhibitors. This is not inherently dangerous in a general population taking no prescription drugs, but it becomes clinically significant for people whose medications have narrow therapeutic windows — meaning the gap between an effective dose and a harmful dose is small. Warfarin, certain antiepileptics, some cardiac drugs, and several immunosuppressants fall into this category. Understanding whether and how strongly fisetin inhibits CYP enzymes is therefore a practical safety question, not just an academic one.
Evidence on Fisetin's Inhibition of CYP Enzymes
Fisetin is a constituent of Rhus verniciflua Stoke (RVS), a plant used in traditional East Asian medicine. Research examining the effects of RVS extract and its individual constituents — including fisetin — on a panel of human cytochrome P450 enzymes found that these compounds exhibited inhibitory activity [2]. Enzyme inhibition by plant-derived flavonoids is a consistent finding across the pharmacology literature and is not unique to fisetin, but it does mean that the CYP interaction concern is not theoretical.
The CYP isoforms most relevant to common drug interactions include CYP2C9, which metabolizes warfarin, and CYP3A4, which handles a broad range of medications including statins, calcium channel blockers, and immunosuppressants. Flavonoids as a class tend to interact with multiple CYP isoforms simultaneously rather than selectively targeting just one. The clinical significance of any given inhibition depends on potency (expressed as an IC50 value), the dose of fisetin consumed, the specific drug being co-administered, and individual variation in baseline CYP activity.
It is important to acknowledge that most CYP inhibition data for fisetin comes from in vitro (cell or enzyme) studies rather than pharmacokinetic studies in humans. In vitro inhibition does not automatically translate to clinically meaningful interaction in a living person, partly because absorbed fisetin concentrations in blood may differ from concentrations used in laboratory assays, and partly because fisetin undergoes its own biotransformation. Human pharmacokinetic data on fisetin remain limited, which means the real-world magnitude of these interactions has not been precisely characterized.
Fisetin and Warfarin: A High-Priority Interaction Concern
Warfarin is among the most interaction-prone drugs in clinical use. Its anticoagulant effect is primarily mediated through inhibition of vitamin K-dependent clotting factors, and its metabolism depends heavily on CYP2C9 (for the more potent S-enantiomer) and CYP1A2 and CYP3A4 (for the R-enantiomer). Because warfarin has a narrow therapeutic window — measured by the International Normalized Ratio (INR) — even modest changes in its metabolism can shift a patient from sub-therapeutic to supratherapeutic levels, increasing the risk of dangerous bleeding.
Beyond CYP-mediated metabolism, some flavonoids can also directly influence platelet aggregation and the coagulation cascade through mechanisms unrelated to liver enzymes. Fisetin, like many polyphenols, has been reported to have antiplatelet properties in preclinical models. If fisetin both inhibits warfarin’s metabolic clearance via CYP2C9 and independently reduces platelet function, the combined effect on bleeding risk could be additive or synergistic. For anyone taking warfarin or other vitamin K antagonists, the co-administration of high-dose fisetin represents an uncharacterized risk that warrants direct discussion with a prescribing physician before proceeding.
Anticoagulants beyond warfarin are also worth flagging. Direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and edoxaban are metabolized through CYP3A4 and are also substrates of P-glycoprotein (P-gp), an efflux transporter. Flavonoids with CYP3A4 inhibitory activity could theoretically increase DOAC plasma concentrations. Dabigatran, which is not a CYP3A4 substrate, may be less affected through this mechanism but is still a P-gp substrate. The specifics have not been studied for fisetin in humans, and extrapolating from in vitro data should be done cautiously.
Other Drug Classes Potentially Affected
CYP3A4 is the most abundant CYP enzyme in the human liver and intestine, and it metabolizes an estimated 50 percent of all marketed drugs. Medications dependent on CYP3A4 that could theoretically be affected by fisetin co-administration include: HMG-CoA reductase inhibitors (statins) such as simvastatin and atorvastatin; immunosuppressants including cyclosporine and tacrolimus; certain calcium channel blockers such as amlodipine and nifedipine; some benzodiazepines; and select HIV antiretroviral agents. The clinical stakes vary widely — cyclosporine toxicity in a transplant patient is a medical emergency, while a modest change in a benzodiazepine’s half-life may have little practical consequence.
CYP2C9 substrates beyond warfarin include some non-steroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, the diabetes medication glipizide, and certain angiotensin receptor blockers like losartan. CYP1A2 substrates include theophylline (a bronchodilator with a narrow therapeutic window), clozapine (an antipsychotic), and caffeine. People taking any of these medications alongside high-dose fisetin should be aware that the interaction landscape has not been mapped in clinical trials and proceed accordingly.
Drug-like property analyses of neuroprotective flavonoid compounds, including evaluation of pharmacokinetic behavior relevant to systemic exposure and potential off-target effects, highlight the importance of fully characterizing small-molecule candidates before assuming clinical safety [1]. This principle applies directly to fisetin: its favorable in vitro and rodent safety profile does not guarantee a clean interaction profile in humans taking polypharmacy regimens.
Why High-Dose Senolytic Protocols Amplify Interaction Risk
The doses of fisetin studied in senolytic research contexts are substantially higher than the amounts provided by dietary sources. A single serving of strawberries delivers only a few milligrams of fisetin; senolytic protocols investigated in animal studies and small human pilots have explored doses in the range of 20 mg/kg body weight taken over two or three consecutive days on an intermittent schedule — equivalent to 1,400 mg or more for a 70 kg adult per dosing day. Supplemental products commonly sold contain 100 to 500 mg per capsule.
Higher doses mean higher peak plasma concentrations, which increases the likelihood that CYP inhibition observed in vitro at high flavonoid concentrations becomes pharmacologically relevant in vivo. If someone taking warfarin consumes 1,000 mg of fisetin on two consecutive days, the transient spike in plasma fisetin could meaningfully slow warfarin clearance, elevating the INR without any change in the warfarin prescription. This is speculative because the human pharmacokinetic data needed to calculate the interaction magnitude simply does not yet exist — but the mechanism is plausible and the risk should not be dismissed.
Fisetin also has relatively poor and variable oral bioavailability due to rapid phase II conjugation and gut microbiota metabolism. Formulation strategies such as nanoencapsulation and liposomal delivery are being developed to enhance absorption. Paradoxically, improved bioavailability — while desirable for putative therapeutic effect — would also increase systemic fisetin exposure and therefore the potential magnitude of CYP-mediated interactions.
Practical Guidance for People Considering Fisetin Supplementation
For individuals who take no prescription medications and have no significant liver or kidney disease, the interaction risk profile of modest fisetin supplementation (100–200 mg daily) is likely low, though this has not been formally established. The evidence for benefit at these doses in humans is also limited, so supplementation remains a personal decision made with incomplete information.
For anyone taking anticoagulants (warfarin, DOACs, heparin derivatives), antiplatelet agents (clopidogrel, prasugrel, aspirin at therapeutic doses), antiepileptics, immunosuppressants, certain antidepressants, or any other drug with a narrow therapeutic window, consultation with a prescribing physician or clinical pharmacist before starting fisetin is genuinely warranted — not merely a legal disclaimer. A pharmacist with access to interaction-checking software can flag which specific CYP pathways your medications rely on and provide a more individualized risk assessment.
If fisetin is introduced while on a sensitive medication, monitoring is prudent. For warfarin users this means more frequent INR checks in the weeks following initiation or dose changes. Patients should inform their healthcare provider that they are taking fisetin and report any unusual bruising, bleeding, or other new symptoms promptly. Stopping fisetin abruptly could also shift the interaction in the opposite direction — suddenly removing an inhibitor could cause drug levels to fall, which has its own implications for medications where under-dosing is dangerous.
🛒 Where to Buy Fisetin
- Life Extension Bio-FisetinLab-tested / studied
capsules, 24 mg per capsule (enhanced-bioavailability liposomal blend) — One of the category’s flagship products; liposomal delivery is designed to improve oral absorption; the lower per-capsule dose requires stacking multiple capsules for research-level senolytic protocols - NOW Foods Fisetin
capsules, 100 mg per capsule — NSF-certified GMP facility; widely available at retail and online; reliable entry-level option for low-dose daily regimens - Double Wood Supplements Fisetin
capsules, 100 mg per capsule (60 count) — USA-manufactured and third-party tested; consistently strong Amazon ratings; popular choice in r/longevity for cost-effective daily use - Swanson Fisetin
capsules, 100 mg per capsule — Established supplement brand with broad distribution; budget-friendly for users wanting a recognizable name at a low cost per dose
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
The evidence base for fisetin’s drug interaction profile is primarily derived from in vitro laboratory studies and extrapolation from related flavonoids; no large-scale human pharmacokinetic trials have directly quantified these interactions at supplemental doses. Individuals taking anticoagulants, immunosuppressants, antiepileptics, or any drug with a narrow therapeutic window should consult a licensed physician or clinical pharmacist before using fisetin supplements — this article is informational only and does not constitute medical advice.
Frequently Asked Questions
Does fisetin definitely interact with warfarin?
No human clinical trial has directly measured this interaction. However, fisetin has demonstrated inhibitory activity against human CYP enzymes in laboratory research [2], and warfarin’s primary metabolic pathway (CYP2C9) is among those potentially affected. Given warfarin’s narrow therapeutic window and the serious consequences of over-anticoagulation, the theoretical concern is clinically meaningful. People on warfarin should not assume it is safe to combine with high-dose fisetin without medical guidance.
Which CYP enzymes is fisetin most likely to affect?
Research on RVS constituents including fisetin identified inhibitory effects on human CYP enzymes broadly [2]. Flavonoids as a chemical class most commonly affect CYP1A2, CYP2C9, and CYP3A4. The specific potency hierarchy for fisetin across individual isoforms in human tissue has not been fully characterized in published clinical pharmacology studies.
Are direct oral anticoagulants (DOACs) like apixaban or rivaroxaban safer than warfarin when taking fisetin?
DOACs are also metabolized via CYP3A4 and are substrates of P-glycoprotein, so they are not necessarily free from interaction risk with flavonoids. They do not require routine INR monitoring the way warfarin does, which means interactions might be harder to detect clinically. There are no published human studies examining fisetin co-administration with any DOAC; anyone on these medications should discuss the question with their prescriber.
Does eating strawberries create the same interaction risk as taking a fisetin supplement?
Dietary fisetin intake from food is orders of magnitude lower than the doses used in senolytic supplementation protocols. A serving of strawberries provides approximately 0.16 mg fisetin per gram of fruit, yielding only a few milligrams total — far below the hundreds or thousands of milligrams in some supplement protocols. Routine consumption of fisetin-rich foods is unlikely to produce clinically significant CYP inhibition, though no formal study has directly tested this threshold.
What does 'drug-like property profiling' mean and why is it relevant to interactions?
Drug-like property profiling evaluates how a compound behaves pharmacokinetically — how it is absorbed, distributed, metabolized, and excreted — and identifies potential off-target effects before clinical use [1]. For fisetin, this type of analysis helps researchers and clinicians anticipate where it might compete with or alter the processing of co-administered drugs. The key takeaway is that favorable properties for one purpose (crossing the blood-brain barrier, for example) can correlate with greater systemic exposure and a wider interaction footprint.
Should I stop taking fisetin suddenly if I start a new prescription medication?
Abruptly stopping a CYP inhibitor can cause drug levels to rise or fall depending on the direction of the previous interaction, which may have clinical consequences for some medications. Rather than stopping without guidance, inform the prescribing physician or pharmacist that you are taking fisetin when a new medication is introduced, so they can advise on timing and whether additional monitoring is appropriate. Do not adjust or stop prescription medications on your own in order to take a supplement.
References
- Lapchak PA et al. Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules. Translational stroke research (2013). PMID 23687519
- Jung H et al. Inhibition of Human Cytochrome P450 Enzymes by Allergen Removed Rhus verniciflua Stoke Standardized Extract and Constituents. Evidence-based complementary and alternative medicine : eCAM (2014). PMID 25061471
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
